Form 4: Verona Pharma Director Sells Shares in Acquisition

Verona Pharma plc director David R. Ebsworth disposed of all beneficial ownership in the company following its acquisition by Merck Sharp & Dohme LLC.

Summary

• David R. Ebsworth, a Director of Verona Pharma plc, reported the disposal of all his beneficial ownership in the company.
• The transactions occurred on October 7, 2025, as a result of a scheme of arrangement under which Verona Pharma plc was acquired.
• The acquisition was executed pursuant to a Transaction Agreement dated July 8, 2025, by and among Verona Pharma plc, Merck Sharp & Dohme LLC (Parent), and Vol Holdings LLC (Bidco).
• At the effective time of the Scheme of Arrangement, each holder of Scheme Shares became entitled to receive $13.375 in cash per Ordinary Share.
• Holders of American Depositary Shares (ADSs) received $107 in cash per ADS, as each ADS represents eight Ordinary Shares.
• Ebsworth disposed of 880,499 Ordinary Shares held directly and 617,600 Ordinary Shares held indirectly through Ebsworth GmbH.
• Additionally, 72,000 time-based restricted share unit (RSU) awards, representing ADSs, fully vested immediately prior to the effective time and were converted into the right to receive cash equal to the ADS Consideration.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of an acquisition where shareholders received a cash premium, indicating a positive and definitive outcome for investors in Verona Pharma plc.

Positives

• Shareholders of Verona Pharma plc received a fixed cash consideration of $13.375 per Ordinary Share or $107 per ADS, representing a clear exit value.
• The successful completion of the acquisition provides a definitive return for investors in Verona Pharma plc.

Negatives

• Verona Pharma plc will cease to be an independent publicly traded entity following the acquisition.

Future Outlook

The filing reports the completion of an acquisition, indicating that Verona Pharma plc will no longer operate as an independent public company. Its future operations will be integrated under Merck Sharp & Dohme LLC.

Industry Context

This acquisition highlights ongoing consolidation within the pharmaceutical and biotechnology sectors, where larger companies often acquire smaller, innovative firms to expand their pipelines or market presence. Such transactions are common strategies for growth and portfolio diversification in the industry.

Stakeholder Impact

• Shareholders received a cash payout for their equity, providing a liquidity event and a defined return on investment.
• Employees holding Restricted Share Unit awards saw these awards fully vest and convert into cash, aligning their interests with the acquisition's success.

Next Steps

• Verona Pharma plc will be integrated into Merck Sharp & Dohme LLC, ceasing its independent public operations.

Key Dates

Keywords

Verona Pharma, VRNA, Merck Sharp & Dohme, acquisition, M&A, Form 4, beneficial ownership, director, scheme of arrangement, restricted share units